Skip to main content
Top
Published in: CEN Case Reports 2/2024

22-08-2023 | Carcinoid Tumor | Case Report

A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective

Authors: Keiko Oda, Tomohiro Murata, Kayo Tsujimoto, Fumika Tanaka, Daisuke Takahashi, Ryosuke Saiki, Yosuke Hirabayashi, Akira Tsunoda, Kanako Saito, Hiroto Yuasa, Hiroshi Imai, Kan Katayama, Kaoru Dohi

Published in: CEN Case Reports | Issue 2/2024

Login to get access

Abstract

Carcinoid syndrome is caused by the release of serotonin and other substances, which commonly occurs due to liver metastasis of neuroendocrine tumors. It rarely occurs due to liver metastasis of neuroendocrine carcinoma. We report the case of a patient with liver metastasis of neuroendocrine carcinoma who suffered from acute abdominal pain and diarrhea triggered by hemodialysis. Various differential diagnoses were considered, but we concluded these symptoms to be probably caused by exacerbation of carcinoid syndrome, as the serum 5HIAA level was markedly elevated, and a drug with anti-serotonin activity was effective. Prochlorperazine maleate, which has anti-serotonin activity, was effective for these symptoms, and the patient was able to continue maintenance hemodialysis, which contributed to his quality of life and prognosis. We speculated the mechanism of carcinoid exacerbation was that substances such as serotonin had entered the systemic circulation via the increased extrahepatic shunt of the portal venous blood flow, entering the inferior vena cava and that this condition had been triggered by hemodialysis via the same mechanism as portal systemic encephalopathy.
Literature
2.
go back to reference Liu EH, Solorzano CC, Katznelson L, et al. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.CrossRefPubMedPubMedCentral Liu EH, Solorzano CC, Katznelson L, et al. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534–45.CrossRefPubMedPubMedCentral
3.
go back to reference Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–34.CrossRefPubMedPubMedCentral Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–34.CrossRefPubMedPubMedCentral
4.
go back to reference Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3–7.CrossRefPubMed Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3–7.CrossRefPubMed
5.
go back to reference Ubara Y, Hoshino J, Tagami T, et al. Hemodialysis-related portal-systemic encephalopathy. Am J Kidney Dis. 2004;44:e38–42.CrossRefPubMed Ubara Y, Hoshino J, Tagami T, et al. Hemodialysis-related portal-systemic encephalopathy. Am J Kidney Dis. 2004;44:e38–42.CrossRefPubMed
6.
go back to reference Klimstra D, Klöppel G, La Rosa S, et al. Classification of neuroendocrine neoplasm of the digestive system. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumours, digestive system tumours. 5th edn, vol. 1. Lyon: World Health Organization; 2019. p. 16–21. Klimstra D, Klöppel G, La Rosa S, et al. Classification of neuroendocrine neoplasm of the digestive system. In: WHO Classification of Tumours Editorial Board, editor. WHO classification of tumours, digestive system tumours. 5th edn, vol. 1. Lyon: World Health Organization; 2019. p. 16–21.
7.
go back to reference Georgiadou F, Moutzouris DA, Kassimatis TI, et al. Recurrent flushing in a hemodialysis patient. Semin Dial. 2006;19:558–9.CrossRefPubMed Georgiadou F, Moutzouris DA, Kassimatis TI, et al. Recurrent flushing in a hemodialysis patient. Semin Dial. 2006;19:558–9.CrossRefPubMed
8.
go back to reference Irvin MM, Mard K, Igor L, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.CrossRef Irvin MM, Mard K, Igor L, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.CrossRef
9.
go back to reference Fandulli G, Ruggeri RM, Glossrubatscher E, et al. Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord. 2020;21:599–612.CrossRef Fandulli G, Ruggeri RM, Glossrubatscher E, et al. Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord. 2020;21:599–612.CrossRef
10.
go back to reference Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2015;52:554–60. Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2015;52:554–60.
11.
go back to reference Sebekova K, Spustova V, Opatrny K Jr, et al. Serotonin and 5-hydroxyindole-acetic acid. Bratisl Lek Listy. 2001;102:351–6.PubMed Sebekova K, Spustova V, Opatrny K Jr, et al. Serotonin and 5-hydroxyindole-acetic acid. Bratisl Lek Listy. 2001;102:351–6.PubMed
12.
go back to reference Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med. 1986;315:663–6.CrossRefPubMed Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med. 1986;315:663–6.CrossRefPubMed
Metadata
Title
A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective
Authors
Keiko Oda
Tomohiro Murata
Kayo Tsujimoto
Fumika Tanaka
Daisuke Takahashi
Ryosuke Saiki
Yosuke Hirabayashi
Akira Tsunoda
Kanako Saito
Hiroto Yuasa
Hiroshi Imai
Kan Katayama
Kaoru Dohi
Publication date
22-08-2023
Publisher
Springer Nature Singapore
Published in
CEN Case Reports / Issue 2/2024
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-023-00814-6

Other articles of this Issue 2/2024

CEN Case Reports 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine